| Abstract: |
Lymphadenectomy is considered as an integral part of radical surgery for urologic malignancies. Many studies have been conducted to confirm its benefit in improving staging accuracy or survival, including in patients with renal cell carcinoma, prostate cancer, and urothelial carcinoma of the bladder. In renal cell carcinoma, the European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 Trial 30881 failed to show any therapeutic benefit of lymphadenectomy. However, this trial has been criticized for enrolling patient at a low risk of lymph node metastases. Other studies have supported the hypothesis that lymphadenectomy may be beneficial in patients with high-risk renal cell carcinoma. © Springer Science+Business Media New York 2015. All rights reserved. |
